• IONIC Brands has developed its sense of where the company belongs within the adult-use cannabis industry by finding where the market is and anticipating where it’s going, technologically
• The company’s West Coast locations are centered in the world’s largest legal recreational cannabis market, and its product line has been developed to specifically cater to consumers’ interests
• IONIC Brands is also preparing to launch its Slim-line Vape pen with Bluetooth technology in the coming weeks – a new development that builds on medical dosing trends to safely and conveniently dose cannabis to recreational users
• The company’s most recent quarterly financial report revealed record revenues that made a 377 percent leap over the prior year’s period

In order to achieve market success, it’s imperative for a company to have a sense of place, both within the terms of the marketplace in which it’s competing and within the geocultural climate where its customers live and breathe every day.

IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) (FRA: IB3) growing a complement of products as a national cannabis holdings company within the recreational adult-use space shows that it knows where it stands and also that it has a prescient idea of where the industry’s road to success is leading.

IONIC Brands is developing a premium and luxury consumer portfolio led by a multi-state consumer-focused cannabis concentrate brand. Its base is on the West Coast, where the adult recreational use market for cannabis is booming with the largest volume of business in the world.

The company’s product line includes six cannabis formulations presented in three distinctive mood offerings designed to appeal to recreational users according to the consumers’ preferences for rich sociability, serene relaxation or enlightened creativity (http://ibn.fm/lRDWW).

The company has also recently closed a successful financing drive to fund various strategic business acquisitions – another part of IONIC Brands’ model for building revenue. In particular, the company’s completion of an exclusive Heads of Agreement with Lifespot Health Limited (ASX: LSH) further demonstrates IONIC’s understanding of how location plays into the success of a cannabis enterprise; the agreement will provide the company with the ability to assimilate short-range Bluetooth technology into its vaporizer hardware.

The connectivity and control that Bluetooth provides within a specific geographic field without inconvenient electronic apparatus additions mean that IONIC Brands can adapt science already successfully used in medicinal applications to manage the dosing aspects of its vaporizer products.

Medical device maker Orthogonal reports that more than 75 percent of its clients use Bluetooth Classic or Bluetooth Low Energy (Bluetooth LE) technologies to ensure connectivity in their wearable, implantable and portable medical devices. Those medical devices comprise a market that Orthogonal expects to exceed $180 billion by next year, even as Bluetooth-equipped smartphones are expected to approach six billion users across the world (http://ibn.fm/OZvFK).

Under the agreement with Lifespot, IONIC Brands expects to upgrade its cannabis vaporizers and develop new vaporizer technologies to better ensure a safe, desirable experience for recreational users.

“Smartphone Bluetooth technology is the future of cannabis delivery and dosing,” Chairman and CEO John Gorst stated in a July news release (http://ibn.fm/omm1l). “The company is ecstatic to offer consumers advanced delivery technology that, before this agreement, was only available to medical patients.”

The company expects to launch the first Bluetooth-enabled vaporizer and platform specifically designed for cannabis use as the Slim-line Vape within the next few weeks.

The company’s visionary approach to its sense of place helped it achieve record revenues for the second quarter reporting period. IONIC ended June with a year-over-year increase of 377 percent in sales, amounting to a $3.86 million increase for the three-month period.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to IONKF are available in the company’s newsroom at http://ibn.fm/IONKF

• The telecommunications industry is preparing for its next evolutionary stage as carriers and their customers begin anticipating 5G data speed enhancements for mobile technology
• Spectrum Global Solutions is an end-to-end provider of telecommunications infrastructure solutions helping to position businesses for the 5G network revolution
• The company recently announced that it has renewed a key three-year contract with a tier 1 carrier for outside plant labor, construction and maintenance services
• Spectrum Global also noted in August that it had been awarded $3.6 million in new contracts with new and existing clients, dealing primarily with 5G network establishment

Telecommunications network service provider Spectrum Global Solutions Inc. (OTCQB: SGSI) announced recently that it has succeeded in renewing a key contract with a U.S.-based tier 1 carrier to which it has previously provided outside plant labor, construction and maintenance services.

The three-year contract with the large-scale telecommunications firm is confidential under the terms of the agreement and based on demand, but Spectrum Global’s announcement notes that a comparable contract with the same company during the prior three-year period generated more than $17.5 million in revenue (http://ibn.fm/dJnz3).

“We believe that these types of contracts will grow to become particularly valuable as the vast investments that carriers are making into their communications infrastructure come to fruition,” CEO Roger Ponder stated in a news release. “It is estimated that the infrastructure cost for 5G alone will exceed $1 trillion, creating an immense opportunity for us to enable carriers to provide improved data connectivity to increasingly data-hungry consumers nationwide.”

5G network rollouts began earlier this year, promising an exponential increase in data transmission speed for the customers of mobile carriers. The technology will be based initially on ‘5G NR’ (5G New Radio) software that relies on existing 4G LTE networks until the carriers evolve with an entirely new infrastructure that will support a more efficient operation (http://ibn.fm/Xakkr).

Spectrum Global is a holding company that serves the needs of the communications technology industry from end to end, with engineering and infrastructure services across the United States, Canada, Puerto Rico, Guam and the Caribbean delivered through its subsidiaries, AW Solutions, ADEX Corp. and TNS Inc.

ADEX won the most recent contract renewal, and Ponder notes that the agreement creates “exciting ancillary opportunities for (SGSI) to win new business for (its) AW Solutions and TNS subsidiaries as well.”

In August, SGSI announced that it had been awarded $3.6 million in new contracts across all of its subsidiaries and that the majority of the contracts involve setting up 5G network infrastructure for new and previously existing clients (http://ibn.fm/YfGC7).

“As we continue to expand our service offering to support the rollout of 5G, which requires a large number of small cell deployments rather than a fewer number of larger towers as was traditionally seen, our opportunity pipeline continues to grow at a rapid rate,” Ponder stated at the time. “I look forward to continued operational execution on this front and long-term shareholder value creation.”

For more information, visit the company’s website at www.SpectrumGlobalSolutions.com

NOTE TO INVESTORS: The latest news and updates relating to SGSI are available in the company’s newsroom at http://ibn.fm/SGSI

• Supreme Cannabis subsidiary 7ACRES recently released its first sativa-dominant strain, with rare sensory characteristics differentiating the high-end flower offering
• Supreme Cannabis is positioned to develop value-add new cannabis products with its acquisition of Truverra
• The company’s collaboration with PAX Labs Inc. creates inroads into the lucrative Canadian vaporizer segment

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a diversified portfolio of cannabis brands that deliver positive experiences, continues to expand through several brand offerings designated for its discerning customer base. Through its various brands, SPRWF continues to synthesize its consumer-driven approach with a strong foundation of business fundamentals to realize promising revenue goals.

Recently, SPRWF announced the initial market entry of Jack Haze, a proprietary strain from its 7ACRES subsidiary. The unique 7ACRES Jack Haze strain is the first of a series designed to differentiate the high-end flower offering of 7ACRES from that of its competitors. That superior quality, the company says, will enable it to maintain premium pricing across Canada. Jack Haze is the company’s first sativa-dominant strain, offering rare sensory characteristics and a crisp and zesty evergreen flavor with visual appeal. The Jack Haze strain will be available in September in select Canadian provinces supplied by 7ACRES (http://ibn.fm/5LWXI).

“This cultivar’s expression possesses a unique haze profile with a classic, sweet sativa smell and strong visual appeal,” Chief Advocacy Officer and Founder John Fowler stated in a news release. “As we develop and introduce unique strains, we further differentiate 7ACRES’ high end flower offering and continue to achieve premium pricing across Canada.”

As the company enhances and expands its flower offering under its 7ACRES brand, it is also taking steps to prepare for ‘Cannabis 2.0’ products in Canada. SPRWF recently acquired Toronto-based and privately held Truverra. This move intensifies Supreme Cannabis’ focus on expanding its cannabis presence in Canada (http://ibn.fm/K9vAr).

Through the acquisition of Truverra, Supreme Cannabis gained a 5,000-square-foot Health Canada licensed facility in Scarborough, Ontario. Truverra’s wholly owned subsidiary, Canadian Clinical Cannabinoids Inc. operates this strategically located and licensed facility. From this operating asset, Supreme Cannabis is preparing to produce high-quality cannabis extracts, including concentrates and vaping liquids.

“The recent introduction of Health Canada’s amended cannabis regulations creates a distinct opportunity for Supreme Cannabis to establish a leading position in the cannabis extracts markets,” SPRWF CEO Navdeep Dhaliwal stated in a news release. “With the acquisition of Truverra, we secure a Toronto-based facility equipped to extract our high-quality inputs for concentrates and vaping liquids in the near-term.”

Deepening its Canadian market presence, Supreme Cannabis has also partnered with PAX Labs Inc. (http://ibn.fm/Akxxr), a market leader with over 1.5 million devices sold worldwide and a “reputation as the best pen-and-pod system in the U.S.” This move allowed Supreme Cannabis to become a foundational brand partner and supplier for the PAX Era in Canada. Supreme Cannabis’ subsidiary, 7ACRES, was one of only four licensed producers chosen to be an initial partner in creating cannabis oil pods for the PAX Era.

Analysts from CFN Media Group (http://ibn.fm/Plad0) noted in a recent report that “nothing speaks more clearly to the ability to scale than Supreme this month providing revenue guidance for the next year in the range of $150 million to $180 million.” The article adds that “the robust growth is owed to management’s ability to make prescient moves to stay in front of regulation changes in addition to operational excellence.”

The Supreme Cannabis portfolio includes 7ACRES, its wholly owned subsidiary and multi-award-winning brand; Blissco Cannabis Corp., a wellness cannabis brand and a multi-licensed processor and distributor based in British Columbia; Truverra Inc., a global medicinal cannabis brand and licensed cultivator; Cambium Plant Sciences, a cultivation IP and plant genetics firm; Medigrow Lesotho, a cannabis oil producer located in southern Africa; Supreme Heights, an investment platform focused on CBD brands in the UK and Europe; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at  http://ibn.fm/SPRWF

• VPR Brands specializes in vaporizers & accessories for essential oils, cannabis concentrates and extracts (CBD), and e-cigarettes containing nicotine
• The company’s assets include issued U.S. and Chinese patents for atomization-related products
• VPR Brands CEO, President and Chairman Kevin Frija recently purchased a significant number of shares of the company

VPR Brands LP (OTCQB: VPRB) is a technology holding company that fosters brands via direct sales and licensing opportunities in the CBD (cannabidiol) vertical. A unique technology enterprise, the company’s assets include patented atomization-related products and technology. VPR Brands had full-year revenues of approximately $4.6 million in 2018 (http://ibn.fm/iB1FH). For Q1 2019, its quarterly revenues increased approximately 31 percent year-over-year to $1.3 million (http://ibn.fm/wjpxq). As his company continues to increase its earnings, CEO, President and Chairman Kevin Frija also continues to invest in it, and he has accrued a significant amount of VPR Brands shares.

VPR Brands’ product family includes vaporizers and accessories for essential oils, cannabis concentrates and extracts, and e-cigarettes that contain nicotine. For investors, the company’s focus is really a fundamental one – to keep adding products and distribution to boost sales and profits. This emphasis helped VPRB attain its revenue achievements in 2018 and so far in 2019.

The company’s experienced and forward-thinking management is also driving its growth. CEO, President and Chairman Kevin Frija recently showed his faith in the company’s direction and strategic initiatives by purchasing a significant number of shares of VPR Brands. Investment analysts often correlate such personal investment from internal leadership with a company’s future potential.

This was the case recently with biopharmaceutical company CTD Holdings Inc. (OTCQB: CTDH), based in Florida. Over the last few weeks, several of its board members personally bought over 500,000 shares of CTDH common stock on the open market. CTD Holdings Chairman and CEO Scott Fine purchased another 50,000 shares in recent weeks, adding to his position. This brings his total ownership to over 6.7 million shares (http://ibn.fm/G3YBd). As one article noted (http://ibn.fm/hgWHO), “When the people close to operations are heavily invested, it is often for good reason and warrants investor attention.”

Similarly, Frija’s support of his company shows his confidence in its growth potential. Pertaining to recent trades, he recently purchased 124,500 shares of company stock on August 19, 2019. Prior to this, Frija purchased 963,860 shares of VPRB on August 16, 2019. Frija owns 10 percent of the company and continues to deepen his support, having bought almost three million shares of VPR Brands since May of this year. These transactions have increased his total share count from greater than 15 million to more than 18 million (http://ibn.fm/zbRFe).

VPR Brands has a diverse line-up of quality brands. These include GoldLine, GoldLine Hemp, HoneyStick, Helium, Vaporin, Krave and VaporX, with HoneyStick being the company’s flagship brand. Additionally, VPR Brands recently entered the CBD space with the GoldLine CBD product line (http://ibn.fm/I2ttF).

VPR Brands continues to focus on building first-rate brands in the nicotine and cannabis marketplaces. The company, with its astute management clearly centered on the major market opportunity in smokables and extracts, offers investors a doorway into booming verticals. VPR Brands is positioned at the crossroads of two industries set to lead the way to future growth.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• The health and wellness industry has been growing in recent years amid increasing efforts to improve quality of life, as well as concerns about the rising costs of medical care
• The global hemp industry is expected to grow at a CAGR of 34 percent between now and 2025 as a subset of the wellness industry
• Texas-based Neutra Corp. is expanding into hemp cultivation and purified hemp extract products under a revenue-generating model that emboldens its strategy for building natural remedies to better the human body and the global environment
• A key part of the company’s strategy involves the recent acquisition of hemp-based health and nutritional product retail brand Vivis Corp. and an LOI to obtain J3 Holdings’ land, warehouse and cultivation license for growing and refining hemp

Neutra Corp. (OTCQB: NTRR) is a company intent on pursuing its interest in developing modern, healthy living solutions in a world that’s ever more focused on quality of life concerns and the rising costs of health care. Neutra Corp.’s initial focus was on bringing to market products derived from all natural and organic origins, as a nutraceutical firm developing natural remedies that promote the body’s ability to heal and maintain itself, when the company was founded in 2011.

The explosion of nutraceutical opportunities in the cannabis derivative market as societal attitudes and governmental regulations have undergone changes in recent years has led Neutra Corp. to pursue the possibility of monetizing early stage research and development efforts to constructively aid the human body and the global environment, scaling vertically with nutraceutical, food and environmental purification holdings.

“In 2019 we’re really looking at trying to figure out how to participate in the hemp-based CBD market,” CEO Sydney Jim said during a recent interview with NetworkNewsAudio (http://ibn.fm/yy7WS). “Our overall goal is to become a vertically integrated company from cultivation to manufacturing to formulation of products and then to distribution and retail sales.”

The wellness industry grew by 6.4 percent each year from 2015 to 2017, topping $4.2 trillion as a market growing nearly twice as fast as the global economy, according to a report issued last fall by The Global Wellness Institute (http://ibn.fm/s6lZR). The global hemp industry is forecast to grow as a segment of the health and wellness market with a CAGR of 34 percent between now and 2025, according to Research and Markets analysts, growing from $4.6 billion to $26.6 billion (http://ibn.fm/W9YOL).

As the global cannabis market continues to grow, it will have a constant need for developing technologies and products that increase business efficiencies in plant cultivation processes, the types of plants to be cultivated and consumption methods. Neutra Corp. is constantly combing the industry for the latest and greatest products to test, prove and bring to market, whether lighting resources, dosage devices, pesticide alternatives or plant nurturing elements, according to the company’s most recent quarterly statement issued September 23 (http://ibn.fm/teboZ).

As part of Neutra Corp.’s strategy for generating revenue, the company recently announced the tactical acquisition of emerging hemp-based health and nutritional product retail brand Vivis Corp. from Jim, who is also Vivis’ founder and CEO. All of Vivis’ CBD products are tested and certified by a third party to ensure their purity (http://ibn.fm/g8KeW).

Vivis has one product line that uses a 99 percent or higher grade of hemp-extracted crystalline CBD, and the company expects to soon launch a second brand with an 80 percent or higher grade of full-spectrum CBD extract.

The company intends to entrust the manufacturing of its products to a nutraceutical contractor to private label all of its products and sell them under Neutra Corp.’s unique brand, according to Neutra Corp.’s quarterly report. The company will continue seeking ways to fund its ventures as a natural part of operations, and it believes that its projects and initiatives will successfully come to provide cash flow that Neutra Corp. can use to finance future growth.

Neutra Corp. has also signed a letter of intent to acquire J3 Holdings, a company that has land, a warehouse and a license to cultivate and refine hemp that are expected to prove valuable additions to Neutra Corp’s stable.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• The consolidation of corporate pharmacy chains and constantly increasing competition are two of the main factors contributing to the problems facing independent and community pharmacies
• The pharmaceutical sector is incredibly lucrative, with large players such as Amazon also attempting to secure part of the market; as a result of such large developments, community pharmacies have been experiencing declining profits and margins
• Trxade Group is working to empower independent pharmacy owners by providing valuable support and information about affordable supplying options; access to real-time information gives small pharmacies the tools needed to compete against large industry players

Growing competition and the consolidation of corporate pharmacy chains are two of the biggest challenges that small and independent pharmacies have to overcome. Companies like Trxade Group Inc. (OTCQB: TRXD) are working on the development of technological solutions that will enable small industry players to remain competitive.

A number of pharmacy chains dominate the prescription drug market in the U.S. Statistics from 2018 suggest that the biggest industry player alone holds 24.2 percent of the market, followed by the second largest chain, which holds 17.5 percent (http://ibn.fm/nLdnb). Adding declining margins to the mix makes it very difficult for small community pharmacies to stay afloat.

One of the latest developments that has impacted the business of small pharmacies in the U.S. is the Amazon acquisition of PillPack (http://ibn.fm/2Qbnc). The deal was concluded in 2018, but the effect it’s having on the pharmaceutical market is only being amplified with the passage of time.

PillPack offers online sales, delivering most of the medications that consumers can get in brick-and-mortar pharmacies. Automatic refills and 24/7 customer support add to the convenience of the service and boost the threat that smaller industry players are facing.

All of these major developments are contributing to a trend that has been ongoing for several years. Since 2016, there has been a sustainable declining profits trend among independent pharmacies (http://ibn.fm/M9wU8). During that year alone, overall gross margins for prescription and non-prescription products were 22.1 percent, in comparison to 24 percent in 2010. As a result of such trends, the number of independent pharmacies has been steadily declining.

However, community pharmacies and small businesses do have an opportunity to fight back and ensure their economic survival. This is where Trxade Group, an integrated pharmaceutical services company that focuses on supporting independent and community-based pharmacies, comes in.

The company’s Trxade Exchange platform creates new and widens existing distribution channels for independent pharmacies. The service enables members of the platform to view manufacturer, wholesaler and buyer group prices. The real-time information makes it easy to access the most affordable supplies and improve overall margins.

As of September 2019, Trxade Exchange’s membership has reached 10,500 pharmacies out of the 24,000 independent entities operating in the U.S. Joining the platform makes it easier for smaller industry representatives to compete with the large retail chains that have solid, affordable supply agreements because they can buy in bulk.

Trxade Group is constantly working to empower small businesses. Apart from its Trxade Exchange platform, the company is developing additional products to maximize data analysis capabilities and inventory management.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• CIIX CEO Warren Wang reported that MicroCap Conference attendees showed interest in the company’s presentation
• In a MoneyTV interview, Wang expressed optimism about the long-range sales of CBD; CIIX will focus on the CBD cosmetics sector
• CIIX reported a 175 percent YOY sales increase for FY2019; industrial hemp and CBD liquor products showed sharp gains

ChineseInvestors.com Inc. (OTCQB: CIIX) CEO Warren Wang said in a MoneyTV interview with host Donald Baillargeon that he was pleased with the reaction to the company’s presentation at the MicroCap Conference, held recently at the Essex House in New York. The presentation was given by Alex Hamilton, CFO of CIIX subsidiary Biotech CBD Inc. (http://ibn.fm/P1TVf).

The conference was designed to bring together high-level institutional and retail investors with publicly held small- and micro-cap companies. Wang noted that he is optimistic about the long-term growth of CBD sales and said that, moving forward, the company plans to focus on cosmetics in the category. According to New Frontier Data, the U.S. hemp CBD market is expected to triple in value by 2022. Likewise, according to Hemp Industry Daily market projections, the national market for hemp-derived CBD is expected to balloon to $7 billion by 2023 (http://ibn.fm/1uxPo).

In addition, CIIX reported sharp gains of 175 percent year-over-year for its FY2019, ended in May 2019. That gain was generated by FY2019 sales of $6,476,442, as compared to $2,353,331 in FY2018, according to its 10-K SEC filing (http://ibn.fm/LIZnq). The increase was driven by industrial-hemp and CBD-liquor product sales of $4,189,935 in FY2019, as compared to $378,984 in FY2018 (http://ibn.fm/PO4wS). Investor relations, a core business for the company, generated gains as well, with sales totaling $1,336,402 in FY2019, as compared to $968,282 the prior year.

Earlier, Wang projected that CIIX sales will reach $11 million to $12 million in FY2020 – the 12 months ending in May 2020. That projection was made during a wide-ranging interview on the Redchip Money Report with host Dave Gentry, broadcast on YouTube. The company has long been reaching a Chinese-speaking audience in the United States and Canada with investment information on issues ranging from cryptocurrency to CBD.

In the same interview, Wang also noted that investors should know that CIIX is seeking to expand its future business. “We are going to do some merger/acquisition to expand our business in the Asian region,” he told the host.

CIIX is a diverse company driven not only by educational services but also by sales of cosmetics, hemp wine and CBD. CIIX offers its audience of Chinese-speaking investors real-time market commentary, analysis and education-related services in Chinese character language sets.

For more information, visit the company’s website at www.ChineseInvestors.com

NOTE TO INVESTORS: The latest news and updates relating to CIIX are available in the company’s newsroom at http://ibn.fm/CIIX

• Independent research carried out by Chinese and Australian scientists shows that the Pressure BioSciences Pressure Cycling Technology (PCT) platform is excellent for the processing of preserved (formalin-fixed paraffin-embedded, or FFPE) and fresh frozen biopsy tissues, which are considered invaluable for discovering cancer biomarkers
• Such tissues play a pivotal role in cancer research and may potentially contribute to the development of therapies and prevention protocols
• Cancer research is one of the more rapidly growing sectors making use of PBIO’s technology; to prepare for further expansion in the future, the company has appointed a new, highly experienced chief financial officer
• The company recently announced that Daniel J. Shea has joined the team as chief financial officer and senior vice president, in anticipation of growth

Pressure BioSciences Inc.’s (OTCQB: PBIO) novel and powerful Pressure Cycling Technology (PCT) platform has performed excellently during the processing of preserved (FFPE) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers, as indicated by two recently published scientific articles about the technology’s performance.

Independent teams of scientists from China and Australia led the research, and their data suggest that the Pressure BioSciences technology could potentially be used in the clinical diagnostic process based on the cancer biomarkers, as the company noted in a press release (http://ibn.fm/DfmC7). Chinese researchers purchased their first two PCT platforms in 2017 and subsequently purchased four additional systems. In Australia, the PCT platform has been in use since 2016.

Because of the large amount of support data on preserved tissue samples like the ones used in the Chinese and the Australian research studies, such samples are considered invaluable for the retrospective study of disease progression and response to therapy. The use of such samples could speed up the discovery of new therapies and preventative strategies, but, up until now, the successful extraction of high-quality biomolecules from FFPE samples has been difficult to accomplish, at best.

According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be key to the discovery of new cancer biomarkers, development of new cancer diagnostics, and release of new treatments and prevention measures, Schumacher concluded.

“We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market,” Pressure BioSciences’ director of marketing and sales Roxana McCloskey added.

The global cancer biomarker market is anticipated to reach more than $157 billion by 2022. This is just one of the multiple important applications of Pressure BioSciences’ innovative pressure-based technology platform.

To prepare for the anticipated growth in the years to come, Pressure BioSciences announced a strategic team addition on September 17, 2019. According to an official company announcement, Daniel J. Shea has joined the team as chief financial officer and senior vice president (http://ibn.fm/3rLyE).

Shea has over 30 years of experience in leading and advising financial organizations. Since the beginning of 2017, Shea has operated a CPA advisory firm called Woodcliff Advisors LLC, which provides counsel to boards, CFOs and members of senior management teams.

“PBIO’s unique platform technologies, worldwide customer base, growing revenue stream, and strong management team position the company well to capitalize on substantial growth opportunities across the globe. I stand ready to support the company’s commitment to high-quality financial reporting and internal control as it navigates through these opportunities in the coming years,” Shea said, commenting on the appointment.

For more information, visit the company’s website at www.PressureBioSciences.com

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

• The Green Organic Dutchman produces high-quality, organic cannabis for the medicinal and recreational adult use markets from purpose-built, state-of-the-art facilities
• The company has confirmed higher demand for premium organic cannabis
• TGOD has also announced positive results from its pharmacokinetic study of innovative cannabinoid technology

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is an international, premium organic cannabis company based in Mississauga, Ontario. The company produces high-quality, organic medical and recreational adult use cannabis using organic craft growing principles. TGOD plans on commercializing organic cannabinoid dissolvables in Canada beginning in December 2019 under the TGOD-Infusers line of premium cannabis products, and results from a recent study have given support to that move. Additionally, TGOD was able to report strong demand for its premium organic cannabis following its Ontario launch and fast-tracked shipments.

Following its Ontario launch and fast-tracked shipments, TGOD reported that there is a strong demand for its premium organic cannabis (http://ibn.fm/wOW3S). After the August launch, initial demand surpassed expectations. The company’s high-THC (tetrahydrocannabinol) signature strain, Unite Organic, performed well both online and at dispensaries, resulting in a second order from the Ontario Cannabis Store – earlier than initially anticipated. The strong launch marks TGOD’s successful entrance into the Canadian recreational market.

While cannabis companies abound, TGOD continues to impress with its organic emphasis and the overall quality of its products. TGOD’s cannabis is grown in its proprietary living soil, in accordance with all-natural principles. Moreover, its growing process is certified organic by Pro-Cert and ECOCERT, two top organic certification bodies. Of note is the fact that, according to a 2019 study conducted by Hill & Knowlton, more than 50 percent of recreational consumers intending to purchase cannabis stated that it is important that their cannabis be organic, and over 60 percent of medical patients prefer organic cannabis. As one of the few certified-organic companies in Canada, these numbers give TGOD an edge in the market.

While TGOD’s premium cannabis products are thriving, the company also plans on introducing organic CBD-dissolvables to the market. In line with that goal, TGOD and Caliper Foods recently reported positive results from a pharmacokinetic study of proprietary, water-soluble cannabinoid technology (http://ibn.fm/JdgjH). The two companies revealed the results of a preliminary human pharmacokinetic (PK) study of Caliper CBD, Caliper Foods’ proprietary tasteless, odorless, water-soluble powder, which can be added to almost any food or beverage. Caliper Foods is a best-in-class provider of water-soluble cannabinoid products.

In the study, half of the participants were administered 30 milligrams of Caliper Foods’ water-soluble CBD powder in eight ounces of water; the other half received 30 milligrams of CBD dispersed in MCT oil. Early data shows that the group that received Caliper CBD demonstrated speedier onset within 15 minutes, with higher concentrations attained at 15 minutes versus the maximum concentration attained at 45 minutes with the CBD-in-oil formulation, and a 4.5-fold higher observed total bioavailability.

“We are thrilled with the results of this preliminary PK study, which demonstrate the consistency and precision of Caliper Foods’ proven proprietary technology, which is already available in Colorado and which TGOD will commercialize in Canada,” TGOD Chief Science Officer Dr. Rav Kumar stated in a news release (http://ibn.fm/J5bPQ). “Based on this early data, Caliper CBD provides a higher and faster absorption level when compared with CBD-infused oil, which opens a number of possibilities for both the medical and adult-use markets.”

With its proven management team and state-of-the-art facilities, TGOD continues to focus on providing a slate of premium consumer-preferred products. The company offers investors potential return on investment as it looks to grow via strategic international opportunities. TGOD’s hybrid facilities represent important advantages over indoor and outdoor greenhouses and set the stage for lower capex and greater profits.

TGOD’s operational emphasis is on medical cannabis markets in Canada, Europe, the Caribbean and Latin America, as well as the Canadian adult-use market. The company’s strategy is to grow organically and at low costs, resulting in a product that demands a premium in the marketplace, thereby increasing the company’s margins.

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Earth Science Tech has launched a new sales division focused on CBD, led by Industry-veteran Erika Franck
• ETST’s portfolio is positioned in the dually lucrative biotechnology and cannabis/cannabidiol industries
• Biotechnology currently represents the largest segment of the growing legal cannabis market

Earth Science Tech Inc. (OTCQB: ETST) recently launched a new sales unit to further strengthen its position in the CBD marketplace for medical and pharmaceutical products. Erika Franck, who has previously served as the company’s clinical and therapeutics sales director, will be heading the division. ETST made this move in accordance with the growing use of CBD in the licensed medical fields and alternate medicinal streams.

The company, under the leadership of Franck, will target medical experts and specialists, suppliers, acupuncturists, chiropractors, practitioners of holistic wellness and alternative therapies, and veterinarians. With the appointment of Franck, the company receives her sound knowledge and experience in the pharmaceutical and orthopedics industry.

“I am thrilled to be part of this amazing team and to have the opportunity to apply my expertise in spearheading this new clinical division for ETST,” Franck stated in a news release (http://ibn.fm/Q84nZ). “Our shared vision is to improve patients’ quality of life, and I am honored to participate in ETST’s continued growth as we achieve this mission.”

Earth Science Tech is well-positioned as a biotechnology company which focuses on the research and development of CBD, pharmaceuticals and medical device products. The company’s pure CBD oil is manufactured using CO2 liquid extraction processes; ETST prides itself on offering the finest quality pure CBD oil on the market.

The biotechnology segment of the cannabis industry consists of pharmaceutical firms focused on the research and development behind new drugs and products that utilize cannabinoids, which are the active compounds within cannabis. Currently the largest sector in the legal cannabis market, it is expected to see further growth as more entities around the world continue researching cannabinoids (http://ibn.fm/icNh9). This trend is encouraging for biotechnology companies like Florida-based ETST.

ETST projects a robust portfolio through its two wholly owned subsidiaries, which are focused on the research and production of cutting-edge industrial hemp and cannabis/cannabidiol (CBD) products to take advantage of the potential seen in the burgeoining cannabis industry.

ETST subsidiary Earth Science Pharma Inc. is engaged in the production of noninvasive economical diagnostic testing tools, medical devices and vaccines for sexually transmitted infections and/or diseases. Their first STI home detection kit using a modified panty liner (MSN-2), named Hygee, is a revolutionary product that can be used for chlamydia testing by women from their homes. The MSN-2 technology is further being utilized to screen for other STIs such as gonorrhea and thichomoniasis, and it holds disruptive potential in the women’s health sector.

Cannabis Therapeutics Inc., another of ETST’s subsidiaries, was formed as an emerging biotechnology company poised to become a world leader in cannabinoid research and development for a broad line of cannabis/cannabinoid-based pharmaceuticals, nutraceuticals and other products and solutions.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST